I. REPORT ON BUSINESS AND PRODUCTION RESULTS IN FEB 2022
(Unit: Billion dongs)
| Criteria |
Feb 2022 |
YTD Feb 28 2022 |
YTD Feb 28 2021 |
Growth rate |
| Total net revenue and other incomes |
63.5 |
160.9 |
198.2 |
(18.8)% |
| Net revenue |
62.6 |
158.8 |
198.1 |
(19.8)% |
| Profit before tax |
11.8 |
30.8 |
34.6 |
(10.7)% |
Total net revenue and other incomes of Imexpharm in the first two months of 2022 was VND 160.9 billion, dropped by 18.8% year over year. The complicated movement of the pandemic, the partially unrecovered market and the long Tet holiday are reasons for this decline in revenue in the beginning months of 2022. However, the Company is actively managing risks of an increase in materials’ prices, transportation fees; therefore, profit before tax decreased by 11.0% compared to the same period of the earlier year. Cost of goods sold plummeted by 27% year over year whilst selling and administrative expenses felt by 4.1% and 10.0% respectively. Imexpharm has been controlling expenditures effectively to maintain profit margin in the context that almost input factors fluctuated. In Feb, Imexpharm sold mainly products manufactured by the Company. There were neither exports nor franchised revenues. In addition, ETC and OTC sales both were reduced in comparison with the figures of last year. Nevertheless, Imexpharm expects revenues of OTC and ETC would increase in the next months when the society is coming back to normality and Covid-19 is considered to be an endemic disease.
II. IMPSTOCK IN FEBRUARY 2021
The total transaction volume of IMP in Feb 2022 attained 11,641,747 stocks. In which, most transactions were conducted via put through the method with the number of 11,374,447 shares, the rest was 267,300 stocks order-matched. In comparison to Feb 2021, the number of IMP order matching volume in Feb 2022 was equal to 25%, simultaneously the number of puts through stocks surged. However, the amount of order matching stocks increased rapidly compared to the figure of Jan 2022 although the market spent for long holiday. In Feb, the major shareholder named KWE Beteiligungen AG has divested at Imexpharm and sold out all stocks of 10,112,023 whereas SK Investment Vina III has raised its ownership at Imexpharm to 46.47%.
III. REMARKABLE ACTIVITIES IN FEB 2022 AND PLANS FOR MAR 2022
In Feb 2022, Imexpharm has purchased 1,693,928 stocks of Agimexpharm Pharmaceutical Joint Stock Company in compliance with the Resolution of the Board of Directors No. 09/NQ-HĐQT-IMP dated May 15, 2022. The ownership rate of Imexpharm at Agimexpharm before and after executing this transaction has not been changed and kept at 32.99%.
In Feb, Imexpharm has disclosed the tentative date for the General Meeting of Shareholders being April 25, 2022, and the date to finalize the list being March 25, 2022.